GLUD2 (Glutamate Dehydrogenase 2)

In addition, PI propelled the metastasis of GH3 cells in vivo, and elevated the expression of PITPNM1, POU1F1, C2orf15 and LDHA. These results suggested that elevated serum PI might contribute to the proliferation and invasion of pituitary adenoma by regulating the expression of PITPNM1/AKT/ERK/POU1F1 axis.

A 4-fold increased prevalence of cancer was observed in men with genetic infertility compared to the general male population (8% vs. 2%; p = 4.4 × 10-3). Expanding genetic testing in andrology will contribute to the multidisciplinary management of SPGF.

Two changes with a strong functional impact occurring at the first evolutionary step, Arg443Ser and Gly456Ala, had a destabilizing and stabilizing effect, respectively, making this step the most important one. Subsequently, GDH2 underwent additional modifications that fine-tuned its enzymatic properties to adapt to the functional needs of modern-day primate tissues.

The classification accuracy using this gene set was 87.5%. These findings suggest the potential of this gene set as a molecular marker for distinguishing grade 3 (AG) from grade 4 (GBM) gliomas.

Furthermore, we investigated the importance of glutamate levels in mitochondrial homeostasis during spermatogenesis by ectopic expression of the mitochondrial glutamate transporter Aralar1, which caused mitochondrial abnormalities in fly spermatids. The data presented in our study offer evidence supporting the significant involvement of glutamate metabolism in sperm development.

Aims: This work investigated the therapeutic potential of Telaglenastat (CB-839), a glutaminase inhibitor, in a CLL cell line, in monotherapy and in therapeutic association with epigenetic modulators - the hypomethylating agents, azacytidine (AZA) and decitabine (DAC), and the histone deacetylates inhibitors, vorinostat (SAHA), and panobinostat (PANO) and with the BTK inhibitor, ibrutinib (IBRU). CB-839 reduced the metabolic activity of HG3 cells in a dose and time-dependent manner (IC 25 : 5nM, IC 50 : 25nM, 48h). Combinations of this glutaminase inhibitor with epigenetic modulators also reduced the metabolic activity (p<0.001), being the synergistic effect of the drug combination more significant with hypomethylating agents (AZA and DAC) and with IBRU. CB-839 induced cytotoxic and cytostatic effects, simultaneously by induced apoptosis and cell cycle arrest in the G0/G1 phase.

Metabolism-related subtypes could be potential biomarkers in the prognosis prediction and treatment of LUAD.